Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells
June 24, 2014 (Source: Accesswire) — Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has publicly released two significant peer-reviewed research papers concerning the destruction of cancer.
The first paper demonstrates the vaccine and immune “memory response” effects of Theralase’s lead Photo Dynamic Compound (PDC), in the destruction of cancer in an animal model. The second paper demonstrates the effectiveness of Theralase’s anti-cancer technology in destroying both normoxic (normally oxygenated) cancerous cells and hypoxic (low oxygenated) cancerous cells.
Theralase’s Vaccine and Immune Memory Response:
Theralase’s research discovered that its lead Photo Dynamic Compound (PDC), intended for the destruction of cancer, demonstrated an ability to render animals immune to repeated exposures of the same cancer. At the 37th Annual American Society for Photobiology on June 16, 2014, in San Diego, California, this peer-reviewed research was presented via poster submission, entitled, “Elicitation of Tumor-free Long-term Survival and Long-lasting Antitumor Memory with Novel Non-immunosuppressive Near-Infrared PDT”
Theralase’s Destruction of Normal and Low Oxygenated Cancer Cells:
As cancerous tumors grow and advance in stage, they can develop areas of hypoxia and even hypoxic cores. These hypoxic areas and cores become resistant to treatment by ionizing radiation and other forms of treatment, including traditional Photo Dynamic Therapy (PDT). By developing state-of-the-art PDC technology that is able to destroy both normoxic and hypoxic cancerous cells, these findings strongly suggest the potential for future application of Theralase’s anti-cancer technology to a wide variety of cancers.
Get our daily investorintel update
“Harnessing of novel visible and near-infrared light photoactivated, Type II/Type I, tunable, metal-based, small molecule, coordination complexes in PDT”, was presented at the conference and details how two additional Theralase PDCs were able to work in both normoxic and hypoxic conditions, strongly suggesting that these PDCs may be suitable in the treatment of more complex, solid core tumors that present with hypoxic areas or hypoxic cores, such as later stage or more developed cancers.
This research has been posted to Theralase’s corporate website at http://www.theralase.com/www2/pdf/elicitation.pdf and http://www.theralase.com/www2/pdf/harness.pdf for review or www.theralase.com under the Press tab.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, “In the first presentation, Theralase’s preclinical trials prove that it is possible to generate a long-term anti-cancer memory response in animals. For the first time in our research program, we have demonstrated that Near Infrared (NIR) PDT leads to long standing clearance of colon cancer cells, but also provides long lasting protection against further tumour cell challenge in young (eight to ten weeks old) and older (ten to eleven month old) mice. This is the first step toward the long-term goal of developing an affordable and practical vaccine to prevent cancer recurrence. The next steps are to further validate this research with additional animals and different cancer cell lines and then translate this research into a human clinical trial. We are collaborating with experts in medical biophysics, immunology and clinical oncology from various internationally acclaimed clinical research institutes to further advance this remarkable platform technology. In the second presentation, Theralase demonstrates an ability of its PDC technology to effectively destroy both normoxic and hypoxic cancerous cells. This suggests an application of this technology to virtually all cancers, including later stage cancers that present with hypoxic areas and cores that can prove resistant to most forms of treatment.”
Roger Dumoulin-White, President and CEO of Theralase stated, “If our PDC technology is proven effective in cancer patients, through human clinical trials slated to commence in early 2015, the implications of this discovery are game changing for both Theralase and for the cancer patients affected. As demonstrated in the first research paper, the ability to destroy the original cancer and also program the body’s immune system to prevent its recurrence, after only a single treatment, is nothing short of miraculous. In the second research paper, demonstration of the ability to destroy virtually all types of cancers, whether normoxic or hypoxic in nature, opens up the potential of new treatment options for a wide range of cancers in various early and advanced stages.”
About Theralase Technologies Inc.
Founded in 1994, Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Link(R)) designs, manufactures and markets patented super-pulsed laser technology which is used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 800 systems in Canada and over 400 systems in the US and international markets to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been so successful in healing nerve, muscle and joint conditions in clinical practice that Theralase’s scientists are now investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (PDCs) which localize to the DNA of cancer cells and then, when activated by light, destroy the cancer cells.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>